Skip to content
Menu

Biomea Fusion, Inc. BMEA

Full chart Compare
Set alert

Price alert · BMEA

All alert types
0.57 USD -0.01 (-2.38%)

Regular-session close

0.60 +0.02 +3.93%

After hours · Nov 20, 7:51 PM ET

0.5445 Day range 0.60
0.488 52-week range 2.21
YTD
-53.68%
1 year
-42.56%

5D +0.0134 (+2.33%)

0.45000.50000.55000.6000FriMonTueWedThu0.5884
Market cap
41.75M
EPS (ttm)
-0.10
Shares out
36.24M
Forward P/E
-1.21
YTD return
-53.68%
1-year return
-42.56%
50-day average
7.91
200-day average
8.85
Enterprise value
74.90M
Volume
1.13M
Avg volume
2.21M
Open
0.563
Previous close
0.5884
Day's range
0.5445 – 0.60
52-week range
0.488 – 2.21
Beta
-0.43
Analysts
Buy
Price target
40.56 (+6960.5%)

Key statistics

Price / book
1.91
Free cash flow
-65.44M
Total cash
87.95M
Total debt
9.57M
Return on equity
-104.51%
Short % of float
44.56%

Fundamental scorecard

4 of 25 checks passed on BMEA’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
BMEA Revenue — quarterly 0
BMEA Net income — quarterly -6.18M
BMEA EPS — quarterly -0.09

Earnings

BMEA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Oct 29, 2024Sep 1, 2024-1.05-0.91+0.14+13.33%
Jul 31, 2024Jun 1, 2024-1.03-1.030.000.00%
Jul 31, 2024Jun 1, 2024-1.03———
May 2, 2024Mar 1, 2024-1.02-1.09-0.07-6.86%
May 2, 2024Mar 1, 2024-1.02———
Apr 1, 2024Dec 1, 2023-0.85-0.98-0.13-15.29%

Upgrades / downgrades

BMEA analyst upgrades and downgrades
DateFirmActionFromTo
Dec 19, 2024D. Boral CapitalmainBuyBuy
Dec 18, 2024HC Wainwright & Co.reitBuyBuy
Dec 17, 2024D. Boral CapitalmainBuyBuy
Dec 16, 2024HC Wainwright & Co.reitBuyBuy
Dec 10, 2024D. Boral CapitalmainBuyBuy
Dec 10, 2024HC Wainwright & Co.reitBuyBuy

About Biomea Fusion, Inc.

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on BMEA — it syncs with the Stock Master app.

Insider holders

BMEA insider holders
InsiderRelationLatest transactionDateShares held
A2A PHARMACEUTICALS INCBeneficial Owner of more than 10% of a Class of SecuritySaleMay 31, 20233,500,000
CHEN BIHUA X.Director and Beneficial Owner of more than 10% of a Class of SecurityPurchaseMar 29, 20230
ERDTMANN RAINER MPresidentStock GiftDec 28, 20232,532,820
FRIAS JUAN PABLOOfficerStock Award(Grant)May 30, 2024349
HITCHCOCK MICHAEL J.M.DirectorPurchaseSep 29, 202415,000
VALLE FRANCOChief Financial OfficerStock Award(Grant)Nov 28, 202442,995

Institution ownership

BMEA institution ownership
Holder% heldSharesValueReported
FMR, LLC14.99%5,431,52521.78MSep 29, 2024
Cormorant Asset Management, LP9.85%3,570,87214.32MSep 29, 2024
Blackrock Inc.6.34%2,296,5939.21MSep 29, 2024
Baker Bros. Advisors, LP5.82%2,108,9498.46MSep 29, 2024
Vanguard Group Inc3.86%1,397,8975.61MSep 29, 2024
Millennium Management Llc3.80%1,378,4085.53MSep 29, 2024

Fund ownership

BMEA fund ownership
Holder% heldSharesValueReported
Fidelity Growth Company Fund4.49%1,625,8376.52MOct 30, 2024
iShares Russell 2000 ETF1.98%718,8682.88MOct 30, 2024
Vanguard Total Stock Market Index Fund1.96%711,7732.85MSep 29, 2024
Fidelity Growth Company K6 Fund1.71%620,2002.49MOct 30, 2024
Fidelity Series Growth Company Fund1.44%520,4272.09MOct 30, 2024
Fidelity Select Portfolios - Biotechnology1.08%392,1291.57MOct 30, 2024